{"abstract": "AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column.", "web_url": "https://dealbook.nytimes.com/2014/05/08/a-case-for-rejecting-pfizers-bid-for-astrazeneca/", "snippet": "AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column.", "lead_paragraph": "Bill George is professor of management practice at Harvard Business School, former chairman and chief executive of Medtronic and author of \u201cTrue North,\u201d a book about authentic leadership. He serves on the boards of ExxonMobil, Goldman Sachs and the Mayo Clinic. In the past two years, he has taught custom leadership programs at Harvard for AstraZeneca executives and consulted with the company in 2012-13. ", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "A Case for Rejecting Pfizer\u2019s Bid for AstraZeneca", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 4, "major": "N"}, {"name": "persons", "value": "Soriot, Pascal", "rank": 5, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 7, "major": "N"}], "pub_date": "2014-05-08T19:35:49+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Bill George", "person": [{"firstname": "Bill", "middlename": null, "lastname": "George", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170", "word_count": 906, "uri": "nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170"}